Spots Global Cancer Trial Database for A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Official Title: A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Study ID: NCT03579082
Conditions
Interventions
Study Description
Brief Summary: To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP for patients with replase and refractory Diffuse Large B cell lymphoma.
Detailed Description: This is a randomized,controlled,prospective,open,multi-center clinical trial,amied to evaluate the safety, tolerability,and efficacy of decitabine combined with R±DHAP in replase and refractory Diffuse Large B cell lymphoma.A total of 60 patients are planned to be enrolled into the study.Patients with diagnosis of replase and refractory Diffuse Large B cell lymphoma will be into two groups,and be treated with decitabine pluse R±DHAP or only R±DHAP,respectively.The primary end points are objective responder rate(ORR) and time to progression(TTP) and the secondary end points include overall survival(OS) and progression free survival(PFS).
Keywords
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Contact Details
Name: Mingzhi Zhang
Affiliation: The first affilliated hospital of zhengzhou university
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
